Skip to content

A single-blind randomized controlled trial of AVS023 poly-herbal formula for Acute low back pain: a pilot study

A single-blind randomized controlled trial of AVS023 poly-herbal formula for Acute low back pain: a pilot study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20141027001
Enrollment
29
Registered
2014-10-27
Start date
2013-03-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute low back pain patient acute Low Back Pain (LBP) anti&#45

Interventions

Ayurved Siriraj Sahatsatara recipe (AVS023) is a poly&#45
herbal formula used in Thai traditional medicine,Ibuprofen is an non&#45
steroidal anti&#45
inflammatory drugs (NSAIDs)
Experimental Drug,Active Comparator Drug
AVS023,Ibuprofen

Sponsors

Faculty of Medicine Siriraj Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Men and women aged 18–65 years, who diagnosed with nonspecific acute LBP. 2. The eligible patients had moderate to severe acute LBP at baseline (score ≥ 4 on an 11-point numerical rating scale [NRS]; 0 = “no pain,” 10 = “pain as very bad as patient can imagine”) for less than 72 hours. 3. Participants were informed by written consent.

Exclusion criteria

Exclusion criteria: 1. Patients who had a history of lumbar and spinal accident in former 1 year or lumbosacral surgery. 2. Patients who had a history of osteoporosis, immunodeficiency, diabetes mellitus, hypertension, cardiovascular disease, thyroid, endocrine gland disease and asthma. 3. Patients who have a current active peptic-duodenal ulcer, gastro-esophageal reflux disease (GERD). 4. Patients who had a history of epilepsy or recurrent seizures; have current active liver disease (abnormal liver function test or aspartate aminotransferase (AST) and alanine aminotransferase (ALT) elevated more than 2 times of upper normal limit). 5. Patients who had creatinine clearance (CrCl) less than 50 ml/min or any significant renal disease. 6. Patients who have blood pressure over 140/90 mmHg; known hypersensitivity to Ibuprofen or AVS023 or herbal and pollen grain. 7. Patients who concomitant use of phenytoin, rifampicin, propranolol, theophylline, corticosteroids, other anti-inflammatory, anticoagulant and antiplatelet in a current medication. 8. Pregnancy or lactating. 9. Patients who required treatment with an opioid analgesic. 10. Patients who prior either drugs NSAIDs, AVS023 or any analgesics, anti-inflammatory and muscle relaxants treatment within 1 week.

Design outcomes

Primary

MeasureTime frame
pain intensity days 1, 3 and 7 numeric rating scale

Secondary

MeasureTime frame
disability days 1, 3 and 7 Oswestry disability index

Countries

Thailand

Contacts

Public ContactSomruedee Chatsiricharoenkul

Faculty of Medicine Siriraj Hospital Mahidol University

somruedee.cha@mahidol.ac.th+66816361717

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026